A fixed-dose combination pill developed by Gilead Sciences has successfully met its primary endpoint in a Phase 3 clinical trial. The ARTISTRY-2 trial results indicate that...
Concerns about the health and safety of inmates at the Niagara Detention Centre emerged after a new dental provider raised issues regarding sanitization practices in late...
ViiV Healthcare has announced that its long-acting HIV pre-exposure prophylaxis (PrEP) therapy, cabotegravir, demonstrated superior acceptability among patients compared to Gilead Sciences‘ lenacapavir in an early-stage...
The Interlake–Eastern Regional Health Authority (IERHA) is expanding its services in response to a significant rise in measles cases in the region. At the annual general...
The Prairie Mountain Health region in Manitoba has experienced a significant rise in HIV cases, escalating from just six reported cases in 2022 to a startling...
